Table 2.
Primary and Secondary Outcomes by CYP2C19 and Antiplatelet Therapy
Clinical outcome by CYP2C19‐P2Y12 inhibitor | Event no.* | Event rate (per 100 patient years) † | Unadjusted HR (95% CI) | P value | Adjusted HR ‡ (95% CI) | P value |
---|---|---|---|---|---|---|
Primary outcome | ||||||
Major atherothrombotic events | ||||||
LOF‐clopidogrel | 71 | 34.4 | Reference | Reference | ||
LOF‐alternative | 51 | 17.1 | 0.50 (0.35–0.72) | <0.001 | 0.56 (0.39–0.82) | 0.002 |
Non‐LOF‐clopidogrel | 197 | 19.9 | Reference | Reference | ||
Non‐LOF‐alternative | 34 | 18.1 | 0.91 (0.63–1.30) | 0.591 | 1.08 (0.72–1.62) § | 0.715 |
Secondary outcomes | ||||||
Major atherothrombotic events at 90 d | ||||||
LOF‐clopidogrel | 40 | 52.5 | Reference | Reference | ||
LOF‐alternative | 20 | 18.9 | 0.37 (0.22–0.63) | <0.001 | 0.40 (0.23–0.71) | 0.002 |
Non‐LOF‐clopidogrel | 104 | 30.8 | Reference | Reference | ||
Non‐LOF‐alternative | 18 | 26.1 | 0.84 (0.51–1.39) | 0.502 | 1.09 (0.64–1.86) | 0.752 |
Clinically significant bleeding events | ||||||
LOF‐clopidogrel | 15 | 7.1 | Reference | Reference | ||
LOF‐alternative | 25 | 7.9 | 1.13 (0.60–2.15) | 0.705 | 1.15 (0.60–2.20) | 0.685 |
Non‐LOF‐clopidogrel | 69 | 6.8 | Reference | Reference | ||
Non‐LOF‐alternative | 15 | 7.4 | 1.10 (0.63–1.92) | 0.745 | 1.30 (0.71–2.38) | 0.397 |
GIB indicates gastrointestinal bleed; HR, hazard ratio; ICH, intracerebral brain hemorrhage; LOF, loss‐of function; and PCI, percutaneous coronary intervention.
Data are presented as the number of patients in each group who experienced the event over 12 months of follow‐up after the index PCI.
The event rate was calculated as the number of events per 100 patient‐years of follow‐up.
The hazard ratio was adjusted with stabilized inverse probability weights derived from exposure propensity scores.
The HR after adjusting for history of GIB or ICH: adjusted HR 1.08; 95% CI, 0.72–1.62; P=0.726.